CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Portfolio Pulse from Vandana Singh
The Centers for Disease Control and Prevention (CDC) has recommended Pfizer's bivalent RSVpreF vaccine (Abrysvo) for pregnant people to protect their newborns from severe RSV illness. This is the first RSV vaccine recommended by the CDC. The vaccine has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth. Pfizer and GSK are competing in the RSV vaccine market, which could exceed $10 billion by 2030. The FDA has also approved GSK's Arexvy and an RSV antibody injection for infants from Sanofi and AstraZeneca.
September 25, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Arexvy has been approved as the first RSV vaccine for older adults worldwide. GSK is competing with Pfizer in the RSV vaccine market.
The approval of GSK's Arexvy could lead to increased sales and boost GSK's stock in the short term. However, competition with Pfizer could impact this.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's RSV vaccine has been recommended by the CDC for pregnant people. This could boost Pfizer's position in the RSV vaccine market.
The CDC's recommendation of Pfizer's RSV vaccine could lead to increased usage and sales, potentially boosting Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi and AstraZeneca's RSV antibody injection for infants has been cleared by the FDA. This treatment is administered directly to babies.
The FDA's clearance of Sanofi and AstraZeneca's RSV antibody injection could lead to increased usage and sales, potentially boosting Sanofi's stock in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 70